FibroBiologics, Inc. Common Stock Market Cap ($22.48 Million)
Market Cap & Net Worth: FibroBiologics, Inc. Common Stock (FBLG)
FibroBiologics, Inc. Common Stock market cap. FibroBiologics, Inc. Common Stock (NASDAQ:FBLG) has a market capitalization of $22.48 Million ($22.48 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24568 globally and #5270 in its home market, demonstrating a 5.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FibroBiologics, Inc. Common Stock's stock price $0.99 by its total outstanding shares 66519722 (66.52 Million). Also see FibroBiologics, Inc. Common Stock cash conversion from operations for how efficiently the company converts equity into cash flow.
FibroBiologics, Inc. Common Stock Market Cap History (2024–2026)
FibroBiologics, Inc. Common Stock market cap history from 2024 to 2026. Data shows change from $146.68 Million to $65.85 Million (-70.64% CAGR). Check FBLG stock price and chart for real-time trading data and today's change.
Index Memberships
FibroBiologics, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #691 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2276 of 3165 |
Weight: FibroBiologics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
FibroBiologics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FibroBiologics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore FibroBiologics, Inc. Common Stock net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of FBLG by Market Capitalization
Companies near FibroBiologics, Inc. Common Stock in the global market cap rankings as of November 4, 2026. Also see FBLG current and non-current assets for a full breakdown of the balance sheet.
Key companies related to FibroBiologics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of FibroBiologics, Inc. Common Stock (2024–2026)
Market capitalization of FibroBiologics, Inc. Common Stock from 2024 to today. Between 2024 and today, FibroBiologics, Inc. Common Stock's market cap moved from $146.68 Million to $ 65.85 Million, with a yearly change of -70.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $65.85 Million | +340.00% |
| 2025 | $14.97 Million | -89.80% |
| 2024 | $146.68 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of FibroBiologics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $22.48 Million USD |
| MoneyControl | $22.48 Million USD |
| MarketWatch | $22.48 Million USD |
| marketcap.company | $22.48 Million USD |
| Reuters | $22.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.